Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1c259T cells in Synovial Sarcoma.

D'Angelo SP, Melchiori L, Merchant MS, Bernstein DB, Glod J, Kaplan RN, Grupp SA, Tap WD, Chagin K, Binder GK, Basu S, Lowther DE, Wang R, Bath N, Tipping A, Betts G, Ramachandran I, Navenot JM, Zhang H, Wells DK, Van Winkle E, Kari G, Trivedi T, Holdich T, Pandite LN, Amado R, Mackall CL.

Cancer Discov. 2018 Jun 11. pii: CD-17-1417. doi: 10.1158/2159-8290.CD-17-1417. [Epub ahead of print]

PMID:
29891538
2.

Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.

D'Angelo SP, Russell J, Lebbé C, Chmielowski B, Gambichler T, Grob JJ, Kiecker F, Rabinowits G, Terheyden P, Zwiener I, Bajars M, Hennessy M, Kaufman HL.

JAMA Oncol. 2018 Mar 22. doi: 10.1001/jamaoncol.2018.0077. [Epub ahead of print]

3.

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.

D'Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, Antonescu CR, Horvath E, Tap WD, Schwartz GK, Streicher H.

Lancet Oncol. 2018 Mar;19(3):416-426. doi: 10.1016/S1470-2045(18)30006-8. Epub 2018 Jan 19.

PMID:
29370992
4.

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.

Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Milella M, Brownell I, Lewis KD, Lorch JH, von Heydebreck A, Hennessy M, Nghiem P.

J Immunother Cancer. 2018 Jan 19;6(1):7. doi: 10.1186/s40425-017-0310-x.

5.

Cytokine release syndrome after radiation therapy: case report and review of the literature.

Barker CA, Kim SK, Budhu S, Matsoukas K, Daniyan AF, D'Angelo SP.

J Immunother Cancer. 2018 Jan 3;6(1):1. doi: 10.1186/s40425-017-0311-9.

6.

Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial.

Chung DJ, Carvajal RD, Postow MA, Sharma S, Pronschinske KB, Shyer JA, Singh-Kandah S, Dickson MA, D'Angelo SP, Wolchok JD, Young JW.

Oncoimmunology. 2017 Sep 21;7(1):e1372081. doi: 10.1080/2162402X.2017.1372081. eCollection 2017.

PMID:
29296525
7.

A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma.

D'Angelo SP, Hamid OA, Tarhini A, Schadendorf D, Chmielowski B, Collichio FA, Pavlick AC, Lewis KD, Weil SC, Heyburn J, Schweizer C, O'Shannessy DJ, Carvajal RD.

Invest New Drugs. 2018 Feb;36(1):103-113. doi: 10.1007/s10637-017-0530-4. Epub 2017 Nov 11.

PMID:
29127533
8.

Is Repeat Pulmonary Metastasectomy Indicated for Soft Tissue Sarcoma?

Chudgar NP, Brennan MF, Tan KS, Munhoz RR, D'Angelo SP, Bains MS, Huang J, Park BJ, Adusumilli PS, Tap WD, Jones DR.

Ann Thorac Surg. 2017 Dec;104(6):1837-1845. doi: 10.1016/j.athoracsur.2017.07.024. Epub 2017 Nov 2.

PMID:
29074153
9.

Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma.

Chudgar NP, Brennan MF, Munhoz RR, Bucciarelli PR, Tan KS, D'Angelo SP, Bains MS, Bott M, Huang J, Park BJ, Rusch VW, Adusumilli PS, Tap WD, Singer S, Jones DR.

J Thorac Cardiovasc Surg. 2017 Jul;154(1):319-330.e1. doi: 10.1016/j.jtcvs.2017.02.061. Epub 2017 Mar 21.

PMID:
28395901
10.

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.

D'Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, Schmidt H, Hassel JC, Hodi FS, Lorigan P, Savage KJ, Miller WH Jr, Mohr P, Marquez-Rodas I, Charles J, Kaatz M, Sznol M, Weber JS, Shoushtari AN, Ruisi M, Jiang J, Wolchok JD.

J Clin Oncol. 2017 Jan 10;35(2):226-235. Epub 2016 Nov 7.

11.

Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab.

D'Angelo SP, Shoushtari AN, Keohan ML, Dickson MA, Gounder MM, Chi P, Loo JK, Gaffney L, Schneider L, Patel Z, Erinjeri JP, Bluth MJ, Sjoberg A, Streicher H, Takebe N, Qin LX, Antonescu C, DeMatteo RP, Carvajal RD, Tap WD.

Clin Cancer Res. 2017 Jun 15;23(12):2972-2980. doi: 10.1158/1078-0432.CCR-16-2349. Epub 2016 Dec 22.

12.

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P.

Lancet Oncol. 2016 Oct;17(10):1374-1385. doi: 10.1016/S1470-2045(16)30364-3. Epub 2016 Sep 1.

13.

Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.

Dickson MA, Mahoney MR, Tap WD, D'Angelo SP, Keohan ML, Van Tine BA, Agulnik M, Horvath LE, Nair JS, Schwartz GK.

Ann Oncol. 2016 Oct;27(10):1855-60. doi: 10.1093/annonc/mdw281. Epub 2016 Aug 8.

14.

Current status of engineered T-cell therapy for synovial sarcoma.

Dallos M, Tap WD, D'Angelo SP.

Immunotherapy. 2016 Sep;8(9):1073-80. doi: 10.2217/imt-2016-0026. Review.

15.

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.

Gounder MM, Zer A, Tap WD, Salah S, Dickson MA, Gupta AA, Keohan ML, Loong HH, D'Angelo SP, Baker S, Condy M, Nyquist-Schultz K, Tanner L, Erinjeri JP, Jasmine FH, Friedlander S, Carlson R, Unger TJ, Saint-Martin JR, Rashal T, Ellis J, Kauffman M, Shacham S, Schwartz GK, Abdul Razak AR.

J Clin Oncol. 2016 Sep 10;34(26):3166-74. doi: 10.1200/JCO.2016.67.6346. Epub 2016 Jul 25.

16.

Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma.

Shoushtari AN, Landa J, Kuk D, Sanchez A, Lala B, Schmidt N, Okoli C, Chi P, Dickson MA, Gounder MM, Keohan ML, Crago AM, Tap WD, D'Angelo SP.

Sarcoma. 2016;2016:3547497. doi: 10.1155/2016/3547497. Epub 2016 May 29.

17.

Manipulating the Immune System With Checkpoint Inhibitors for Patients With Metastatic Sarcoma.

D'Angelo SP.

Am Soc Clin Oncol Educ Book. 2016;35:e558-64. doi: 10.14694/EDBK_161901. Review.

18.

Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.

Dickson MA, Schwartz GK, Keohan ML, D'Angelo SP, Gounder MM, Chi P, Antonescu CR, Landa J, Qin LX, Crago AM, Singer S, Koff A, Tap WD.

JAMA Oncol. 2016 Jul 1;2(7):937-40. doi: 10.1001/jamaoncol.2016.0264.

19.

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.

Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page DB, Postow MA, Weinstein A, Lucas AS, Ciccolini KT, Quigley EA, Lesokhin AM, Paik PK, Chaft JE, Segal NH, D'Angelo SP, Dickson MA, Wolchok JD, Lacouture ME.

Cancer Immunol Res. 2016 May;4(5):383-9. doi: 10.1158/2326-6066.CIR-15-0123. Epub 2016 Feb 29.

20.

Reply to A. Indini et al.

Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo KM, Panageas KS, Wolchok JD, Chapman PB.

J Clin Oncol. 2016 Mar 20;34(9):1018-9. doi: 10.1200/JCO.2015.65.7007. Epub 2016 Jan 19. No abstract available.

PMID:
26786917
21.

A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.

Munhoz RR, D'Angelo SP, Gounder MM, Keohan ML, Chi P, Carvajal RD, Singer S, Crago AM, Landa J, Healey JH, Qin LX, Hameed M, Ezeoke MO, Singh AS, Agulnik M, Chmielowski B, Luke JJ, Van Tine BA, Schwartz GK, Tap WD, Dickson MA.

Oncologist. 2015 Nov;20(11):1245-6. doi: 10.1634/theoncologist.2015-0245. Epub 2015 Oct 8.

22.

Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas.

Gounder M, Desai V, Kuk D, Agaram N, Arcila M, Durham B, Keohan ML, Dickson MA, D'Angelo SP, Shukla N, Moskowitz C, Noy A, Maki RG, Herrera DA, Sanchez A, Krishnan A, Pourmoussa A, Qin LX, Tap WD.

Eur J Cancer. 2015 Nov;51(16):2413-22. doi: 10.1016/j.ejca.2015.06.109. Epub 2015 Aug 19.

23.

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.

Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo KM, Panageas KS, Wolchok JD, Chapman PB.

J Clin Oncol. 2015 Oct 1;33(28):3193-8. doi: 10.1200/JCO.2015.60.8448. Epub 2015 Aug 17.

24.

Corrigendum to "Sarcoma Immunotherapy: Past Approaches and Future Directions".

D'Angelo SP, Tap WD, Schwartz GK, Carvajal RD.

Sarcoma. 2015;2015:259817. doi: 10.1155/2015/259817. Epub 2015 Jun 9.

25.

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma.

Dickson MA, D'Adamo DR, Keohan ML, D'Angelo SP, Carvajal RD, Gounder MM, Maki RG, Qin LX, Lefkowitz RA, McKennon OR, Hirst CM, Schwartz GK, Tap WD.

Sarcoma. 2015;2015:532478. doi: 10.1155/2015/532478. Epub 2015 May 14.

26.

Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma.

D'Angelo SP, Munhoz RR, Kuk D, Landa J, Hartley EW, Bonafede M, Dickson MA, Gounder M, Keohan ML, Crago AM, Antonescu CR, Tap WD.

Oncology. 2015;89(4):205-14. doi: 10.1159/000381917. Epub 2015 Jun 3.

27.

Rapid eradication of a bulky melanoma mass with one dose of immunotherapy.

Chapman PB, D'Angelo SP, Wolchok JD.

N Engl J Med. 2015 May 21;372(21):2073-4. doi: 10.1056/NEJMc1501894. Epub 2015 Apr 20. No abstract available.

28.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J.

Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18.

PMID:
25795410
29.

Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma.

D' Angelo SP, Mahoney MR, Van Tine BA, Adkins DR, Perdekamp MT, Condy MM, Luke JJ, Hartley EW, Antonescu CR, Tap WD, Schwartz GK.

Cancer Chemother Pharmacol. 2015 Mar;75(3):629-38. doi: 10.1007/s00280-015-2689-8. Epub 2015 Feb 12.

30.

Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment.

D'Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin LX, Carvajal RD, Dickson MA, Gounder M, Keohan ML, Schwartz GK, Tap WD.

Hum Pathol. 2015 Mar;46(3):357-65. doi: 10.1016/j.humpath.2014.11.001. Epub 2014 Nov 15.

31.

Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.

Chaft JE, Litvak A, Arcila ME, Patel P, D'Angelo SP, Krug LM, Rusch V, Mattson A, Coeshott C, Park B, Apelian DM, Kris MG, Azzoli CG.

Clin Lung Cancer. 2014 Nov;15(6):405-10. doi: 10.1016/j.cllc.2014.06.002. Epub 2014 Jun 21.

PMID:
25044103
32.

Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation.

Kadota K, Yeh YC, D'Angelo SP, Moreira AL, Kuk D, Sima CS, Riely GJ, Arcila ME, Kris MG, Rusch VW, Adusumilli PS, Travis WD.

Am J Surg Pathol. 2014 Aug;38(8):1118-27. doi: 10.1097/PAS.0000000000000246.

33.

Sarcoma immunotherapy: past approaches and future directions.

D'Angelo SP, Tap WD, Schwartz GK, Carvajal RD.

Sarcoma. 2014;2014:391967. doi: 10.1155/2014/391967. Epub 2014 Mar 20. Review. Erratum in: Sarcoma. 2015;2015:259817.

34.

High-risk features in radiation-associated breast angiosarcomas.

D'Angelo SP, Antonescu CR, Kuk D, Qin L, Moraco N, Carvajal RC, Chi P, Dickson MA, Gounder M, Keohan ML, Singer S, Schwartz GK, Tap WD.

Br J Cancer. 2013 Oct 29;109(9):2340-6. doi: 10.1038/bjc.2013.590. Epub 2013 Oct 8.

35.

Ipilimumab for patients with advanced mucosal melanoma.

Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwartz GK, Chapman PB, Gnjatic S, Wolchok JD, Hodi FS, Carvajal RD.

Oncologist. 2013 Jun;18(6):726-32. doi: 10.1634/theoncologist.2012-0464. Epub 2013 May 28.

36.

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

Dickson MA, Tap WD, Keohan ML, D'Angelo SP, Gounder MM, Antonescu CR, Landa J, Qin LX, Rathbone DD, Condy MM, Ustoyev Y, Crago AM, Singer S, Schwartz GK.

J Clin Oncol. 2013 Jun 1;31(16):2024-8. doi: 10.1200/JCO.2012.46.5476. Epub 2013 Apr 8.

37.

Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.

D'Angelo SP, Janjigian YY, Ahye N, Riely GJ, Chaft JE, Sima CS, Shen R, Zheng J, Dycoco J, Kris MG, Zakowski MF, Ladanyi M, Rusch V, Azzoli CG.

J Thorac Oncol. 2012 Dec;7(12):1815-22. doi: 10.1097/JTO.0b013e31826bb7b2.

38.

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.

Dogan S, Shen R, Ang DC, Johnson ML, D'Angelo SP, Paik PK, Brzostowski EB, Riely GJ, Kris MG, Zakowski MF, Ladanyi M.

Clin Cancer Res. 2012 Nov 15;18(22):6169-77. doi: 10.1158/1078-0432.CCR-11-3265. Epub 2012 Sep 26.

39.

Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.

Paik PK, Johnson ML, D'Angelo SP, Sima CS, Ang D, Dogan S, Miller VA, Ladanyi M, Kris MG, Riely GJ.

Cancer. 2012 Dec 1;118(23):5840-7. doi: 10.1002/cncr.27637. Epub 2012 May 17.

40.

Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.

D'Angelo SP, Pietanza MC, Johnson ML, Riely GJ, Miller VA, Sima CS, Zakowski MF, Rusch VW, Ladanyi M, Kris MG.

J Clin Oncol. 2011 May 20;29(15):2066-70. doi: 10.1200/JCO.2010.32.6181. Epub 2011 Apr 11.

41.

The molecular pathogenesis of small cell lung cancer.

D'Angelo SP, Pietanza MC.

Cancer Biol Ther. 2010 Jul 1;10(1):1-10. Review.

PMID:
21361067
42.

A case series of dose-limiting peripheral edema observed in patients treated with pemetrexed.

D'Angelo SP, Kris MG, Pietanza MC, Rizvi NA, Azzoli CG.

J Thorac Oncol. 2011 Mar;6(3):624-6. doi: 10.1097/JTO.0b013e318207f788.

43.

Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.

Janjigian YY, Park BJ, Zakowski MF, Ladanyi M, Pao W, D'Angelo SP, Kris MG, Shen R, Zheng J, Azzoli CG.

J Thorac Oncol. 2011 Mar;6(3):569-75. doi: 10.1097/JTO.0b013e318202bffe.

44.

[The molecular pathogenesis of small cell lung cancer].

D'Angelo SP, Pietanza MC.

Zhongguo Fei Ai Za Zhi. 2010 Nov;13(11):C46-57. doi: 10.3779/j.issn.1009-3419.2010.11.18. Review. Chinese. No abstract available.

45.

Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center.

D'Angelo SP, Park B, Azzoli CG, Kris MG, Rusch V, Ladanyi M, Zakowski MF.

J Thorac Cardiovasc Surg. 2011 Feb;141(2):476-80. doi: 10.1016/j.jtcvs.2010.08.026. Epub 2010 Oct 8.

Supplemental Content

Loading ...
Support Center